Skip to main content
. 2021 Jan 4;131(1):e138315. doi: 10.1172/JCI138315

Figure 8. SF3B1K700E mutation sensitizes breast cancer cells to AKT inhibitors.

Figure 8

(A) Western blot of MCF7 cells expressing an empty vector (EV), SF3B1 WT, or SF3B1 K700E cDNA. (B) IC50 of MCF7 cells shown in A following 5 days of exposure to MK2206 (left) or GDC0068 (right). Data are represented as mean ± SD; n = 6. (C) Western blot of MCF10A WT cells as well as SF3B1K700E/WT knockin cells, PIK3CAH1047R/WT knockin cells, and SF3B1K700E/WT PIK3CAH1047R/WT double knockin cells cultured in the absence of EGF. (D) IC50 to MK2206 of MCF10A cells shown in C in the presence or absence of EGF. Data are represented as mean ± SD; n = 6. (E) Clonogenic survival assay of MCF7 cells shown in A following 21 days of exposure to MK2206. IC50 curve is shown at right. (F) Clonogenic survival assay of MCF710A cells shown in C following 14 days of exposure to MK2206 in absence of EGF. IC50 curve is shown at right. See also Supplemental Figures 13 and 14.